Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392889 | 1.00 | CA1 (1.00) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL2724764 | 1.00 | CA1 (1.00) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL21356989 | 1.00 | CA1 (1.00) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL391423 | 0.97 | — | — | |
| SCHEMBL2723676 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL29819829 | 0.93 | CA1 (0.88) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL1486989 | 0.90 | — | — | |
| Carbamic Acid SCHEMBL3668356 | 0.87 | CA1 (0.75) | CA1CA2POLBTSHRKMT2A | |
| Piperidine SCHEMBL6170163 | 0.84 | CA2 (0.71) | CA1CA2POLBTSHRKMT2A | |
| Carbamic Acid SCHEMBL1269504 | 0.83 | CA1 (0.70) | CA1CA2POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110072864-A | TDO2 INHIBITORS | 基因泰克公司 | 2019-07-30 | — | — | CN | claimed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-110072864-A | TDO2 INHIBITORS | 基因泰克公司 | 2019-07-30 | — | — | CN | disclosed |
| US-20180346416-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| US-10071957-B2 | N-substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| EP-2870138-B1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-104797555-B | N-substituted benzamides and methods of use thereof | 基因泰克公司 | 2017-12-22 | — | — | CN | disclosed |
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| CN-104797555-A | N-substituted benzamides and methods of use thereof | GENENTECH INC | 2015-07-22 | — | — | CN | disclosed |
| EP-2870138-A2 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014008458-A2 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| EP-2650284-A1 | Heterocyclic derivatives as metabotropic glutamate receptor modulators | Merz Pharma GmbH & Co. KGaA (DE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, SNRPD2, RDX | CA1 2618/4885CA2 2585/4885POLB 2326/4885 |
| US-10071957-B2 | N-substituted benzamides and methods of use thereof | BRIX1, SNRPD2, RDX | CA1 2618/4885CA2 2585/4885POLB 2326/4885 |
| US-20180346416-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, P2RX3 | CA1 2544/4885CA2 1725/4885POLB 3296/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | CA1 3102/4885CA2 2478/4885POLB 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.